ReviewInternational journal of molecular sciences2020
Prevention of Diabetes and Cardiovascular Disease in Obesity.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05987410 (EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Diabetic patiEnts With Cardiovascular Disease. The VENERE Study), which is not on this map. Cited by 95 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Diabetic patiEnts With Cardiovascular Disease. The VENERE Study
Who cites it
95 citing papers in PubMed, 5 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- The effectiveness and usability of online, group-based interventions for people with severe obesity: a systematic review and meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Obesity effect on newly diagnosed and recurrent post-ablation atrial fibrillation: a systematic review and meta-analysis.Journal of endocrinological investigation · 2024Pooled it
- The role of serotonin hormone on weight loss maintenance after sleeve gastrectomy: a systematic review.Journal of medicine and life · 2024Pooled it
- Association of parathyroid hormone with risk of hypertension and type 2 diabetes: a dose-response meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Pooled it
- Nutraceutical Properties of Thai Mulberry (Nutrients · 2024Trial
- Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial.BMC complementary medicine and therapies · 2023Trial
- Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.Journal of diabetes research · 2022Trial
- GULP1 enhances GLUT4 translocation by counteracting ACAP1-ARF6 inhibition.Nutrition & diabetes · 2026Article
- Systematic comparison of triglyceride-glucose (TYG)-index with other mortality predictive models in obese patients with different mortality rates.Cardiovascular diabetology · 2026Article
- Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4.Cardiovascular diabetology · 2026Article
- Diet-Induced Browning of White Adipose Tissue: Molecular Targets, Mechanisms, and Therapeutic Potential.Current issues in molecular biology · 2026Review
- Improving glucose tolerance in obese rats: the role of Jinlida granules ( ) in gut microbiota modulation.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Recombinant Macrophage Migration Inhibitory Factor Derived fromInternational journal of molecular sciences · 2026Article
- Prediabetes: a new indication for GLP-1s?International journal of obesity (2005) · 2026Review
- A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.Journal of obesity · 2026Review
- Pathogenesis of impaired glucose tolerance in rats based on transcriptome analysis.Scientific reports · 2025Article
- The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review.Biochemistry and biophysics reports · 2025Review
- Body mass index (BMI) associates with frequency of arterial hypertension and type 2 diabetes in obese patients candidates for bariatric surgery.Cardiovascular diabetology · 2025Article
- Histidine-Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Obesity is one of the major risk factors for the development of both impaired glucose tolerance (IGT, or prediabetes) and type 2 diabetes (T2D), and its prevalence worldwide drives toward an increased rate of cardiovascular morbidity and mortality. Given the estimations of the World Health Organization (WHO) and the recommendation of the Diabetes Prevention Program (DPP), where IGT and diabetes are considered as risk factors for the development of cardiovascular complications and obesity, the development of diabetes should be treated because of its potential reversibility. In this view, several interventions such as diet, lifestyle changes, and pharmacological treatment are effective, including bariatric metabolic surgery (BMS), which is the most incisive way to efficiently lower body weight. In this review, we sought to summarize some of the major aspects linked to diabetes prevention in overweight/obesity, focusing on the use of surgery; we also attempted to elucidate molecular pathways involved in a variety of obesity-induced processes able to favor the progression of chronic diseases, such as diabetes and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.